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ABSTRACT 
Purpose: Powdered sevelamer carbonate is a new phosphate binder with unproven therapeutic benefit in Indian population. Hence, we 
aimed to compare its efficacy and safety with calcium acetate in patients with Chronic Renal Disease on hemodialysis. 
Methods: This was a randomized, prospective, cross over and open labeled study, conducted in the Department of Nephrology, 
Christian Medical College and Hospital, Ludhiana. Fifty patients were included in data analysis and were randomization into two 
groups, A & B. Group A patients first received powdered sevelamer carbonate for  4 weeks (n= 25) followed by 1 week of washout and 
calcium acetate for the next 4 weeks (n=25). Group B: vice-versa.  Serum phosphorus, calcium, C-reactive protein (CRP), total 
cholesterol, triglycerides (TGs) and low density lipoprotein (LDL) levels were performed before and after each drug was administered.  
Results: Mean baseline serum phosphorus and calcium phosphorus product in group A, reduced from 6.59 ± 0.31mg/dl & 53.18 ± 
2.5mg2/dl2 to 5.26± 0.33mg/dl & 44.76mg2/dl2 respectively. In group B these reduced from 6.42±0.33 mg/dl & 52.06±2.5 mg2/dl2 to 
5.44±0.3 mg/dl & 44.5mg2/dl2 respectively. The reduction in these values in both groups was statistically significant (p<0.05). 
Reductions in serum CRP, total cholesterol, triglycerides and low density lipoprotein (LDL) levels were not statistically significant in 
either group.  
Conclusion: Powdered sevelamer carbonate and calcium acetate are equally efficacious with no serious adverse effects. Both the drugs 
were well tolerated. Hence, powdered sevelamer carbonate can be a useful alternate to calcium based binders in Indian patients. 
Keywords: powdered sevelamer carbonate, calcium acetate 
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INTRODUCTION:  
Hyperphosphatemia is a debilitating consequence of 
chronic renal disease (CRD). Its long term complications 
are renal osteodystrophy, hyperparathyroidism, and 
increased cardiovascular calcification leading to 
increased mortality and morbidity
1–4
. It can be controlled 
by restricting phosphorus in the diet, oral phosphate 
binders (PB) and dialysis. Dietary restriction on 
phosphate is possible only up to a limit before it 
adversely affects nitrogen balance. Dialysis can remove 
up to 70 % of ingested phosphorus
5
. Hence, for long 
term phosphorus control, patients are prescribed oral 
PBs. Until recently calcium based PBs were the main 
stay of treatment but upon including lifetime cost and 
quality adjusted life-years gained sevelamer may gain 
approval
6
.  
Sevelamer carbonate is a non-metal oral PB also used to 
treat hyperphosphatemia. Its efficacy is proven in 
western population
6-8
. Unlike metal based oral PB, it is a 
cross linked polymer containing multiple amine groups. 
Its powdered form allows it to be sprinkled on food like 
salt before consumption, and may prove valuable for 
patients with difficulty swallowing or chewing. It binds 
to phosphorus in the food, making it unavailable for 
absorption. It is excreted in the feces. It is also shown to 
lower serum low density lipoprotein (LDL), triglyceride 
(TG), C- reactive protein (CRP) and lipids
8,9
. C- reactive 
protein (CRP) is an acute phase reactant. However, when 
it is raised for prolonged periods of time it denotes 
arterial inflammation. Hence, raised CRP is a biomarker 
for sudden deaths in CRD patients
10–12
. Phosphate 
binders (PB) are used to control serum phosphorus. 
Powdered formulation has an advantage of mixing well 
with food before consumption, hence preventing 
absorption. In Indian population few studies have been 
done comparing sevelamer with calcium based PBs
13,14
. 
However, these studies used hydrochloride form that has 
its own disadvantages. They were done over a short 
period in small patient population. Furthermore, there 
has been no study in India that has compared powdered 
form of sevelamer carbonate to calcium acetate. Hence, 
this study was designed to study the effect of powdered 
sevelamer carbonate with calcium acetate in patients 
with chronic renal disease on hemodialysis. 
MATERIALS AND METHODS: 
This was a prospective, open labeled, cross-over, 
comparative and randomized study, conducted in patients 
undergoing maintenance hemodialysis (for ≥6 weeks) in 
the Department of Nephrology, Christian Medical 
College (CMC) and Hospital, Ludhiana. The study was 
conducted after obtaining approval of the Institute 
Research Committee. The study design was explained to 
all the patients. All patients were provided with study 
information and written informed consent was obtained 
before any intervention.  
Patients with chronic renal disease (CRD) of both 
genders, over 18 years of age, undergoing hemodialysis 
were included. Those with hypercalcaemia, severe GI 
disorder, any malignancy, breast feeding women and 
known hypersensitivity to phosphate binders were 
excluded. 
 
Figure: 1 Study design 
All patients were given a washout period of 1 week 
during which no PB was administered. At the end of 1 
week all biochemical parameters were done. If the serum 
phosphorus level was greater than 4.5 mg/dl the patients 
was randomized in either group (A or B). Randomization 
was done according to a computer generated random 
number table. Group A patients were given powdered 
sevelamer carbonate in a dose of 400 mgs three times a 
day for the first 4 weeks (n= 25). They were asked to 
sprinkle it on food like salt and stir well. At the end of 4 
weeks all biochemical parameters were repeated. This 
was followed by one week of washout period at the end 
of which all biochemical parameters repeated, followed 
by tablet calcium acetate (667mgs) three times a day for 
the next 4 weeks (n=25). At the end of 4 weeks all 
biochemical parameters were repeated again. The 
calcium acetate tablets were consumed with food or 
immediately after finishing the meal. The same procedure 
was repeated with group B patients but they were given 
tablet calcium acetate for the first 4 weeks followed by 
powdered sevelamer carbonate for the next 4 weeks. 
Figure 1. 
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The biochemical parameters included serum phosphorus, 
calcium, LDL, TG, Cholesterol and CRP. All data was 
recorded in the patient particular sheet.  Unpaired t-test 
was done to determine if there was a statistically 
significant difference in the biochemical values after both 
washouts in the two groups. Since this was insignificant 
(p=0.711), it was decided to combine pre drug data. At 
the end of the study, data of 50 patients (25+25) who had 
taken powdered sevelamer carbonate was collected, and 
done similarly for patients who had taken calcium 
acetate. The total duration of the study was 10 weeks. 
The study design is depicted in Figure1. Consort chart is 
given in Figure 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: 2. Consort diagram. 
Adverse Drug Reaction (ADR) recording was also done 
at every follow up and hemodialysis visit for each patient. 
Both the study drugs (powdered sevelamer carbonate and 
calcium acetate) along with the investigations were 
funded by Emcure Pharmaceutical Ltd., Pune, India. The 
patients did not bear any additional cost by participating 
in the study. The company had no role in the study design 
or evaluating the study results or the preparation of this 
manuscript. 
Statistical analysis: 
To compare Sevelamer carbonate group with Calcium 
acetate group, a sample of 100 patients was required 
(n=50 each group) to achieve 80% power. All statistical 
tests used for comparisons of the 2 treatment periods 
were 2 tailed, with probability value of less than 0.05 
required for significance. Sample size was calculated 
using OpenEpi version 3.0.1. The values are expressed as 
mean ± SD (standard deviation). SPSS 21.0, Armonk 
NY: IBM corp. was used to analyze the data. 
RESULTS 
We screened 209 patients, out of which 159 were 
excluded: 154 due to low serum phosphorus after the 
washout period, 1 patient refused to participate, 3 patients 
had history of questionable compliance with medication 
and 1 patient had no requirement for phosphate binder.  
Fifty patients who met the inclusion criteria were 
included in the study. Out of these 31 were men. The 
1-Refused consent  
1- Did not require phosphate binder   
3- Had history of questionable compliance 
204 patients given washout for 1 week 
154 patients did not have hyperphosphatemia  
209 patients screened  
50 patients randomized  
1 week washout  
Group A (4 weeks) 
(n=25) powdered sevelamer carbonate   
Group A (4 weeks) 
(n=25) calcium acetate 
Group A (4 weeks) 
(n=25) powdered sevelamer carbonate   
 
Group B (4 weeks) 
(n=25) calcium acetate 
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mean age and demographic profile of patients were comparable between the groups. It is given in Table 1.  
 
Table 1: Baseline demographic characteristics 
 
At 0 week, between group A and B, mean serum 
phosphorus, calcium, calcium phosphorus product, 
serum cholesterol, TG, LDL and CRP were comparable. 
At the end of 4 weeks, reduction in serum phosphorus 
(Figure 3) and calcium phosphorus product (Figure 4) 
was significant in both the groups when compared to 
baseline (p<0.05). However, this significance was lost 
when comparison was made in-between the two groups 
(p>0.05). There was no significant change in calcium, 
LDL, TG, CRP level at 4 weeks and when comparison 
was made between groups A and B(p>0.05). The 
baseline and 4 week values are given in Table 2.
 
Table 2: Baseline and 4 week biochemical investigations results 
 
Parameter 
(mg/dl) 
Group A Group B 
0 week 4 weeks 0 week 4 weeks 
Serum Phosphorus 6.65±2.11 5.26±2.22
*
 6.42±2.35 5.44±2.19
*
 
Serum Calcium 8.1±0.13 8.5±0.13 8.2±0.22 8.2±1.03 
Calcium Phosphorus Product 
(mg
2
/dl
2
)  
54.18±17.23 44.44±18.47
*
 52.06±17.95 44.54±18.31
*
 
Total Cholesterol 122.89±34.33 122.950±37.64 126.98±39.38 122.62±35.38 
LDL 66.81±25.59 56.82±27.67 72.76±33.34 69.50±28.88 
TG 124.77±72.16 116.27±57.72 113.02±59.52 117.96±72.67 
CRP 2.11±5275 2.49±5.84 2.74±4.85 2.38±3.44 
*p<0.05 compared to 0 week 
# p<0.05 compared to group A 
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Figure 3. Phosphorus level in both groups at 0 and 4 weeks 
0 week 
4 weeks 
*p<0.05 as compared to 0 week 
#p<0.05 as compared to 4 weeks of  group A 
Baseline characteristics Group A(n=50) Group B (n=50) 
Age (years) 52.08 47.64 
Gender (M/F) 15:10 16:9 
Etiology  
Hypertension (mm Hg) 16 17 
Diabetes Mellitus  8 8 
Polycystic kidney disease (PCKD) 1 0 
*p<0.05 as compared to Group A 
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Safety profile  
In this study diarrhoea was the only adverse effect 
reported by two patients in group A. First patient was 
given de-challenge and a re-challenge. He reported 
diarrhoea again after re-challenge and was taken off the 
study. It was 8 on Naranjo’s scale. Second patient in the 
same group also reported diarrhoea which was self-
limiting. No adverse effects were reported in group B. In 
the current study both PB were equally safe since there 
was no hypercalcaemia seen in calcium acetate arm or 
hypocalcaemia seen in sevelamer carbonate arm.  
DISCUSSION: 
Both powdered sevelamer carbonate and calcium acetate 
were equally efficacious in reducing hyperphosphatemia 
in patients with chronic renal disease (CRD). Baseline 
demographic profile; age, gender and aetiology; were 
comparable in both groups. The mean age of patients in 
this study was similar to earlier studies done in India but 
lower than that of USA
11-13
.
 
It strengthens the evidence 
that CRD affects younger population in India
16,17
. In this 
study number of men was higher; although this disease is 
known to affect women more often than men. This trend 
is also observed in other studies in India
17,18 
The most 
common etiology of CRD reported from India is diabetic 
nephropathy followed closely by systemic hypertension; 
although in this study it was systemic hypertension. This 
data further adds to the need of studies that will elucidate 
age, gender distribution and etiology of CRD specifically 
for India. 
In this study, serum phosphorus was lowered equally by 
both PB. There was no statistical difference when 
phosphorus lowering was compared in between the two 
groups. Various international studies comparing these PB 
in adult population have also deduced the findings of this 
study
19,20
 An Indian study also supports this finding 
although the cohort were pediatric population
13,14
.  
Reduction in calcium phosphorus product was significant 
in both groups although this significance was lost in 
intergroup analysis. This finding is supported by the 
Indian study done on pediatric age group
14
. It however, 
had limited sample size and was not done in adults. The 
same results were reflected in other international studies 
also done in both pediatric 
20 
and adult population
21
. 
Although sevelamer has shown beneficial effects in 
lowering cholesterol, LDL, TG, current study did not 
show any significant reduction in either group.
22
 It could 
perhaps be due to the short duration of the study. CRP is 
an acute phase reactant, elevated CRP levels are 
associated with increased cardiovascular mortality in 
CRD
23
. This study did not deduce significant reduction 
in CRP levels in either group. To the best of our 
knowledge, no study in Indian setup has compared CRP 
as primary or secondary outcome.  
Safety: Both PBs were well tolerated as seen in other 
studis
24
 although only one case of hypercalcaemia has  
been reported from a long term study
25
. In this study 
however, the adverse events were less as compared to 
these earlier studies. Both sevelamer carbonate and 
calcium acetate are well tolerated drugs. 
CONCLUSION: 
Hence, from the data of this study we conclude that 
powdered sevelamer carbonate does not reduce 
cholesterol levels significantly when given for 4 weeks 
(short term). Both powdered sevelamer carbonate and 
calcium acetate are equally effective in lowering serum 
phosphorus. Both are well tolerated. Hence, it can be 
used as an alternative to calcium based PBs in lowering 
phosphorus levels in Indian population. Moreover, the 
powdered form has its own advantages with patients who 
have difficulty chewing and swallowing.  
Compliance with Ethical Standards:  
This study was performed in accordance with ethical 
standards of the institutional research committee and 
with the 1964 Helsinki declaration and its later 
amendments.  The study was approved by the institute 
research and ethics committees.  
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Figure 4. Calcium Phosphorus product in both groups at 0 and 4 weeks 
0 week 4 weeks *p<0.05 as compared to 0 week 
#p<0.05 as compared to 4 week of  group A 
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